Our study aims to investigate the underlying molecular mechanism of FCRLA and MMP2 in RCC development, with the goal of identifying promising diagnostic biomarkers and effective immunotherapeutic targets for RCC treatment. This evidence concerns the gene FCRLA and renal cell carcinoma.